Vir
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs innovative approaches to manipulate immune responses through its four technology platforms, which target antibodies, T cells, innate immunity, and small interfering RNA. Its product pipeline includes candidates for hepatitis B, influenza A, human immunodeficiency virus, and tuberculosis. Vir collaborates with various organizations, including the Bill & Melinda Gates Foundation and National Institutes of Health, and has established agreements with companies like Alnylam Pharmaceuticals and Brii Biosciences. Additionally, the company has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Founded in 2016, Vir Biotechnology seeks to leverage its scientific expertise to transform the landscape of infectious disease management.
Agenovir Corporation is focused on the research and development of antiviral therapeutics aimed at addressing diseases related to latent or persistent viral reservoirs. Established in 2014 and based in South San Francisco, California, the company employs innovative nucleases, including CRISPR/Cas9 technology, to target and disrupt viral DNA. This approach allows for the creation of a new class of nucleic acid-based antiviral treatments that aim to eliminate pathogenic viral genomes. Agenovir's mission is to provide effective solutions for healthcare providers treating patients suffering from severe and chronic viral infections, ultimately advancing the field of antiviral therapeutics. As of January 31, 2019, Agenovir operates as a subsidiary of Vir Biotechnology, Inc.
Humabs BioMed SA, founded in 2004 and based in Bellinzona, Switzerland, specializes in developing human monoclonal antibody platforms aimed at treating infectious and inflammatory diseases. The company collaborates with pharmaceutical firms and academic institutions, leveraging its CellClone technology to create innovative therapies. Humabs has two clinical-stage partnered programs, notably working with MedImmune, AstraZeneca's biologics research arm, on an antibody targeting the influenza A virus, which has shown efficacy against all known subtypes and has completed phase 1b/2a trials. Additionally, Humabs is partnered with Novartis on an antibody project currently in phase 2. The company's focus on anti-infective immunotherapies addresses significant medical needs, providing new treatment options for both common and rare diseases. As of 2017, Humabs operates as a subsidiary of Vir Biotechnology, Inc.
TomegaVax Inc. is an immunotherapy company that specializes in the development of a novel vaccine technology platform aimed at addressing chronic and recurring viral infections. The company's focus is on creating vaccines and immunotherapies for significant health challenges such as Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV), and Herpes Simplex Virus (HSV). TomegaVax's platform is designed to provide continuous low-level antigen presentation, which helps to maintain an active T-cell-mediated immune response. This innovative approach allows for the potential treatment of previously difficult-to-treat viral infections, offering new hope for patients in need of effective therapeutic options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.